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Abstract
Introduction: The use of fluorodeoxyglucose-positron emission tomography to evaluate well-differentiated
hepatocellular carcinomas is facing critical problems. It is reported that the activity of fluorodeoxyglucose-
6-phosphatase, which converts fluorodeoxyglucose-6-phosphatase to fluorodeoxyglucose, is high in normal liver
cells. However, the enzyme-converting activity of glucose-6-phosphatase of well-differentiated hepatocellular
carcinomas is similar to normal liver tissue. Thus, using fluorodeoxyglucose in diagnosing primary hepatocellular
carcinomas is difficult. However, using fluorodeoxyglucose to detect extrahepatic metastasis of hepatocellular
carcinomas is still possible.
Case presentation: We describe the case of a 45-year-old Chinese woman who developed a recurrent lesion in
the chest wall from a previous surgically resected hepatocellular carcinoma. This recurrent lesion was detected first
on the basis of a positron emission tomography scan, then on the basis of a computed tomography scan and
other clinical tests.
Conclusion: This finding indicates that the positron emission tomography scan is a potentially reliable tool to
screen for systemic metastatic disease in patients with hepatocellular carcinomas when other cross-sectional
imaging tests such as computed tomography or magnetic resonance imaging are negative.
Introduction
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer worldwide [1]. It has a high mortality rate,
with most patients succumbing to the disease within
one year [1]. The presence of metastatic disease in these
patients markedly reduces survival [2]. Recently, the
occurrence of liver cancer in the United States of Amer-
ica has been increasing because of the increased fre-
quency of hepatitis C [3]. Liver cancer tends to spread
to nearby lymph nodes, bones and lungs. In rare cases,
it spreads to the chest wall with or without identified
primary liver cancer. It is essential to diagnose HCC in
its early stages to ensure patient survival [2,4]. Ultra-
sound, computed tomography (CT), magnetic resonance
imaging (MRI) and positron emission tomography (PET)
are the primary imaging methods for the diagnosis of
liver cancer [5]. The PET scan is an emerging imaging
modality that measures and distinguishes the increased
rates of glucose metabolism and oxygen consumption in
tumor tissue from normal surrounding tissue. The
advantage of PET scans is that they measure metabolic
changes at the cellular level [6]. On the other hand,
cross-sectional imaging modalities such as CT, ultra-
sound, and MRI detect anatomical changes. Thus, PET
scans allow complementary anatomical detection and
measurement of cellular activity in tumors. However,
the average false-negative rate of PET scans is 40% to
50% for the detection of HCC because of active glucose
metabolism in normal hepatic parenchyma. It has been
demonstrated that glycolysis metabolism within HCC is
equivalent to or less than that of normal liver tissue.
Therefore, most primary HCCs are underdetected by
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PET scans [7,8]. However, PET scans have shown benefit
in the detection of early metastasis in extrahepatic sites,
especially in the frequent metastatic organs, such as the
colon, lung, brain and lymph nodes [9,10]. In this
case report, we describe a chest wall metastasis of HCC
that was uniquely detected by PET scan but not by
CT scan. This report indicates that whole-body PET
is a potentially valuable method to screen for the early
presentation of extrahepatic metastatic disease.
Case presentation
A 45-year-old Asian woman with a known history of hepa-
titis C for 20 years had received no interferon treatment
for her hepatitis C. The patient developed HCC and
underwent successful surgical resection with a negative
surgical margin. Her pathological specimen allowed the
diagnosis of well-differentiated HCC in postsurgical fol-
low-up, and the patient underwent CT scans every three
months, alternating with ultrasound. All results of these
scans were reported to be unremarkable except for post-
surgical changes. A blood test was also done, including
measurement of a-fetoproteins (AFPs). One year later the
patient’s AFP was slightly elevated at 25 mg/dL (normal
range, <10 mg/dL). Repeated CT scans and ultrasounds of
the patient’s abdomen revealed no changes from previous
examinations. Upon physical examination, the patient was
noted to have small induration areas over the upper-left
chest wall and under the left clavicle bone with a size of
approximately 1 × 1 cm2. The patient denied any trauma
or pain related to the area. Because AFP levels continued
to increase to 40 mg/dL, a PET scan was ordered. For PET
imaging, the patient was injected with 10.9 mCi of
18F-fluorodexyglucose (FDG). One hour later the patient
voided and underwent PET with or without attenuation
correction. Imaging was performed in multiple acquisi-
tions to include the face, neck, chest, abdomen, pelvis and
proximal thighs. Images were acquired using 2-D imaging
and reconstructed in three planes. 3-D tomographic
reconstruction and analysis were carried out.
The PET scan showed a focus of slightly elevated FDG
uptake in the left infraclavicular region with a standar-
dized uptake value of 2.0 (Figures 1a and 1b). It was
interpreted as showing possible metastatic disease. How-
ever, the CT scan was interpreted as showing no residual
tumor or metastatic disease. Subsequently, the patient
underwent resection of a palpable subcutaneous nodule
not visualized on the CT scan, but correlated with the
above-described PET scan abnormality in the left infra-
clavicular region. The patient’s pathological examination
confirmed metastatic HCC of the chest wall.
Discussion
HCC is the third highest cause of cancer mortality
worldwide, and the incidence of HCC in the United
States is increasing [4]. The etiology of HCC is believed
to be from hepatitis B and C, but its increased incidence
is due to metabolic disorders such as diabetes. The diag-
nosis of HCC is dependent upon AFP, tissue biopsy and
imaging studies. Although ultrasound, CT and MRI
have been widely used to detect HCC, PET has
remained out of favor for the diagnosis of HCC because
of the lack of differentiation between HCC glucose
metabolism and normal liver tissue. However, on the
basis of a literature search, the PET scan has shown
promise in distinguishing extrahepatic metastatic tumors
from normal surrounding tissue. The reports show that
the sensitivity of PET is about 80%, its specificity is 75%
to 90% and its accuracy is around 80% [9,10]. Thus,
PET may detect early extrahepatic HCC lesions in clini-
cal follow-up. In the reported studies, the PET scan has
been successfully used in detecting extrahepatic HCC
lesions such as those of the lymph node, lung, bone,
vasculature and adrenal gland. However, some uncom-
mon metastatic sites of HCC, such as skin or soft tis-
sues, have not been detected by PET or have not been
reported yet. On the other hand, lesions in these tissues
can be missed by using CT or MRI technologies. The
PET scan, by measuring elevated glucose metabolism in
tumors, has shown promise in distinguishing extrahepa-
tic metastatic tumors from normal surrounding tissue
[9,10]. Thus, the use of PET in clinical follow-up may
be beneficial in detecting early metastatic HCC lesions
which are not defined in the liver.
In the patient described in the present report, the chest
wall tumor that developed from HCC was detected by
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Figure 1 (a) Metastatic lesion in chest wall was markedly positive
for uptake with tracer (arrow). (b) The corresponding computed
tomographic image reveals that no lesion can be identified.
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obtaining a PET scan as the earliest step, in comparison
to a CT scan. This result provided very valuable and
unique information that affected the patient’s treatment
plan. The patient underwent immediate local resection of
the metastatic lesion in accordance with the standard
treatment guideline [11]. Furthermore, the patient was
started on sorafenib treatment as a first-line targeted
therapy immediately after the PET scan identified the
metastatic lesion over the chest wall. The response to
sorafenib treatment provides further progression-free sur-
vival. Therefore, the early diagnosis of a metastatic lesion
on the basis of a PET scan ensures a better prognosis for
the patient, initiation of the most accurate therapy and
increased patient survival. Although most HCC metas-
tases occur in the gastrointestinal tract, lung and bone,
HCC does metastasize to many other organs, including
the chest wall [12]. Therefore, it is important to be able
to identify these lesions in an imaging study such as a
PET scan, as in our present case, where PET was the
only tool that successfully detected a pathologically pro-
ven chest wall metastasis. Although further investigation
is needed with larger groups of patients to validate the
superiority of PET to detect extrahepatic metastatic dis-
ease in patients with HCC, we believe it is a promising
method, in combination with other studies, to detect rare
sites for metastatic disease. Even though the PET scan is
regarded as an insensitive method for the detection of
primary HCC, one clinical study did demonstrate that
18F-FDG PET/CT had a relatively high sensitivity in
detecting extrahepatic HCC lesions [13].
Conclusion
It has been reported that the PET scan provides addi-
tional information for the diagnosis of extrahepatic
HCC [9,14] and is an important tool for surveillance of
distant metastasis in patients with unexplained AFP ele-
vation after HCC treatment [15]. Therefore, we suggest
that the use of whole-body 18F-FDG PET/CT be consid-
ered in the follow-up of patients with HCC for potential
early detection of systemic metastatic extrahepatic
disease.
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